NDAINJECTIONSUSPENSION
Approved
Oct 2021
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
14
Data completeness
4/8 — Partial
XIPERE (triamcinolone acetonide) by Bausch + Lomb is corticosteroid hormone receptor agonists [moa]. First approved in 2021.
Drug data last refreshed 9h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
XIPERE is a triamcinolone acetonide suspension administered via injection, functioning as a corticosteroid hormone receptor agonist. It is indicated for ophthalmic use to reduce inflammation and manage corticosteroid-responsive conditions in the eye. The drug works by binding to corticosteroid receptors to suppress inflammatory pathways.
Peak13.8 years to LOE
Product in peak commercialization phase with established reimbursement, indicating stable mid-size brand team focused on market penetration.
Mechanism of Action
Corticosteroid Hormone Receptor Agonists
Pharmacologic Class:
Corticosteroid
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (14)
Drug-Drug Interaction Study of Lorecivivint and Triamcinolone Acetonide in Healthy Volunteers
Started Oct 2020
40 enrolled
Drug-Drug Interaction
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Anti-VEGF in Subjects With Macular Edema Following RVO
Started Mar 2018
325 enrolled
Macular EdemaRetinal Vein Occlusion
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
Started Jan 2017
460 enrolled
Macular EdemaRetinal Vein Occlusion
Posterior Subtenon Versus Intravitreal Injection of Triamcinolone Acetonide for Treatment of Uveitic Cystoid Macular Edema
Started Nov 2015
0UveitisCystoid Macular Edema
Suprachoroidal Injection of Triamcinolone Acetonide With IVT Aflibercept in Subjects With Macular Edema Following RVO
Started Jan 2015
46 enrolled
Macular EdemaRetinal Vein Occlusion
Worked on XIPERE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.